Home Newsfeeds CNBC Earlier Reported ‘Citi Expands Program To Help Diverse Communities Reach ‘transformational’ Homeownership Milestone. Here’s Who Qualifies’

News

CNBC Earlier Reported ‘Citi Expands Program To Help Diverse Communities Reach ‘transformational’ Homeownership Milestone. Here’s Who Qualifies’

https://www.cnbc.com/2022/09/09/citi-expands-program-to-increase-homeownership-in-diverse-communities.html?utm_source=dlvr.it&utm_medium=twitter

byBenzinga Newsdesk

September 9, 2022

1 minute read

https://www.cnbc.com/2022/09/09/citi-expands-program-to-increase-homeownership-in-diverse-communities.html?utm_source=dlvr.it&utm_medium=twitter

SCWorx Shareholders Overwhelmingly Approve 1-For-15 Reverse Stock Split At Annual Meeting

By Benzinga Newsdesk

October 10, 12:24 PM

SCWorx Corp. (NASDAQ:WORX) announces the successful conclusion of its 2023 Annual Meeting of Stockholders (the "Meeting"). The Meeting yielded significant positive outcomes, instilling confidence in the Company amongst

WORX

Oppenheimer Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $78

By Benzinga Newsdesk

August 18, 11:27 AM

Oppenheimer analyst Justin Kim maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target from $68 to $78.

APLS

Berenberg Assumes Ascendis Pharma at Buy, Announces Price Target of $166

By Benzinga Newsdesk

August 30, 5:10 AM

Berenberg analyst Caroline Palomeque assumes Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $166.

ASND

What’s Going On With MicroStrategy Stock Tuesday?

By Adam Eckert

April 30, 9:25 AM

MicroStrategy Inc (NASDAQ:MSTR) shares are trading lower Tuesday after the company reported worse-than-expected financial results for the first quarter.

BTC

CNBC Earlier Reported ‘Citi Expands Program To Help Diverse Communities Reach ‘transformational’ Homeownership Milestone. Here’s Who Qualifies’

Related Posts

SCWorx Shareholders Overwhelmingly Approve 1-For-15 Reverse Stock Split At Annual Meeting

Oppenheimer Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $78

Berenberg Assumes Ascendis Pharma at Buy, Announces Price Target of $166

What’s Going On With MicroStrategy Stock Tuesday?